Cancer Research

NCCN and Pfizer Fund Projects to Improve Prostate Cancer Care
Management & Regulatory NCCN and Pfizer Fund Projects to Improve Prostate Cancer Care

Reducing the logistical and financial hurdles associated with prostate cancer treatment is a primary goal of the latest round of quality improvement funding. This initiative, spearheaded by the National Comprehensive Cancer Network Oncology Research Program in partnership with Pfizer Global Medical

Can Biomimetic Membranes Revolutionize Intestinal Modeling?
Biotech & Bioprocessing Can Biomimetic Membranes Revolutionize Intestinal Modeling?

The historical reliance on rigid synthetic substrates for intestinal research has created a significant gap between laboratory observations and the soft, flexible reality of living human tissue. For decades, scientists have struggled to replicate the physiological environment of the gut using

Combining Viruses and CAR-T Therapy to Fight B-Cell Cancers
Research & Development Combining Viruses and CAR-T Therapy to Fight B-Cell Cancers

By inducing the lysis of malignant cells, oncolytic viruses release a broad spectrum of neoantigens that can prime a patient’s native immune system through a process called epitope spreading. This mechanism represents a significant shift from the current clinical standard of single-target Chimeric

Challenges and Opportunities for Personalized mRNA Cancer Vaccines
Tech & Innovation Challenges and Opportunities for Personalized mRNA Cancer Vaccines

The current pharmaceutical landscape is witnessing a profound transformation as the successful clinical implementation of personalized mRNA cancer vaccines begins to redefine the standard of care in oncology. This seismic shift is driven by a long-held vision: the ability to train a patient’s own

What Is the Next Frontier in Oncology Innovation?
Research & Development What Is the Next Frontier in Oncology Innovation?

The oncology sector is shifting its primary focus from simply managing terminal disease to achieving functional cures that allow patients to live long, healthy lives. This transition marks a departure from the historical reliance on broad-spectrum treatments that often came with debilitating side

FDA Approves Guardant360 CDx for Serial Breast Cancer Care
Research & Development FDA Approves Guardant360 CDx for Serial Breast Cancer Care

The approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant marks the first time a liquid biopsy has been authorized for continuous monitoring of cancer evolution. This regulatory milestone fundamentally alters the management of advanced breast cancer by allowing

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later